Li M, Shioda S, Somogyvári-Vigh A, Onda H, Arimura A
Department of Medicine, Tulane University Medical Center, New Orleans, LA, USA.
Endocrine. 1997 Oct;7(2):183-90. doi: 10.1007/BF02778140.
Pituitary adenylate cyclase activating polypeptide (PACAP) is a new member of the secretin/VIP family of peptides. The specific receptor for PACAP has been cloned in rat, human, and bovine tissues. The distribution of the transcripts of PACAP receptor genes has been studied in various tissues using in situ hybridization. However, the unavailability of a specific antibody against the PACAP receptor has hampered further study of the expression of receptor proteins. In the present study, rabbit antisera were generated against a synthetic 25-residue peptide corresponding to the C-terminal intracellular domain of the rat PACAP receptor. To validate the specificity of the antisera, CHO cells and cells stably transfected with rat PACAP receptor cDNA were prepared. Using one of these antisera, the membrane and soluble fractions of the transformants were examined by Western blot analysis. Three bands were observed in subcellular fractions from the transfected CHO cells, but no bands were found in similar preparations from the nontransfected cells. A distinct 57-kDa band, which corresponds to the size of cloned rat PACAP receptor, was detected. In addition, a less intense band, larger than 57 kDa, and a very weakly stained band, smaller than 57 kDa, were demonstrated. All of these bands disappeared or were considerably diminished when the antiserum was preabsorbed with the synthetic immunogen peptide. This suggests that these bands are PACAP receptor-related proteins. The membranes from the transfected CHO cells bound to [125I]PACAP27. The size of the ligand/protein crosslinked product approximated 60 kDa, corresponding to the combined size of the PACAP receptor and PACAP27. No additional bands were observed, indicating that the immunopositive proteins larger or smaller than 57 kDa do not bind to the ligand and are not functional. Unlabeled PACAP27 and PACAP38, but not VIP, displaced the binding, suggesting that the receptors expressed in CHO cells are specific for PACAP. Solubilized membrane fractions prepared from rat brains were used for an immunoprecipitation study with [125I]PACAP27 and [125I]VIP. The PACAP receptor antiserum recognized [125I]PACAP-, but not [125I]VIP-bound proteins in the solubilized brain membrane fractions. Immunohistochemistry using this antiserum showed a distribution of PACAP receptor-like immunoreactivities similar to the distribution of the mRNA of PACAP receptor in the rat brain. Thus, the PACAP receptor antiserum is sufficiently specific to be used as a tool for studying the expression of PACAP receptors and related proteins.
垂体腺苷酸环化酶激活多肽(PACAP)是促胰液素/VIP肽家族的新成员。PACAP的特异性受体已在大鼠、人类和牛组织中克隆出来。已使用原位杂交技术在各种组织中研究了PACAP受体基因转录本的分布。然而,缺乏针对PACAP受体的特异性抗体阻碍了对受体蛋白表达的进一步研究。在本研究中,制备了针对与大鼠PACAP受体C末端胞内结构域相对应的25个氨基酸残基合成肽的兔抗血清。为了验证抗血清的特异性,制备了CHO细胞和稳定转染大鼠PACAP受体cDNA的细胞。使用其中一种抗血清,通过蛋白质印迹分析检测转化体的膜和可溶性部分。在转染的CHO细胞的亚细胞部分中观察到三条带,但在未转染细胞的类似制备物中未发现条带。检测到一条明显的57 kDa带,其大小与克隆的大鼠PACAP受体的大小相对应。此外,还显示出一条强度较低、大于57 kDa的带和一条染色非常弱、小于57 kDa的带。当抗血清用合成免疫原肽预先吸收时,所有这些条带消失或明显减少。这表明这些条带是PACAP受体相关蛋白。转染的CHO细胞的膜与[125I]PACAP27结合。配体/蛋白质交联产物的大小约为60 kDa,与PACAP受体和PACAP27的组合大小相对应。未观察到其他条带,表明大于或小于57 kDa的免疫阳性蛋白不与配体结合且无功能。未标记的PACAP27和PACAP38,但不是VIP,取代了结合,表明在CHO细胞中表达的受体对PACAP具有特异性。用[125I]PACAP27和[125I]VIP对从大鼠脑制备的可溶性膜部分进行免疫沉淀研究。PACAP受体抗血清识别可溶性脑膜部分中与[125I]PACAP结合但不与[125I]VIP结合的蛋白质。使用该抗血清的免疫组织化学显示,PACAP受体样免疫反应性的分布与大鼠脑中PACAP受体mRNA的分布相似。因此,PACAP受体抗血清具有足够的特异性,可作为研究PACAP受体和相关蛋白表达的工具。